Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer

16. november 2026 oppdatert av: Shanghai JMT-Bio Inc.

A Multicenter, Randomized, Controlled Phase Ⅲ Clinical Study on the Efficacy and Safety of Glumetinib in Combination With Osimertinib as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With Classic EGFR Mutations and MET Overexpression or Amplification

To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

375

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Clinical Trials Information Group officer
  • Telefonnummer: 031169085587
  • E-post: ctr-contact@cspc.cn

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Able to understand and willingness to voluntarily provide written informed consent.
  2. Age 18 to 75 years, males or females.
  3. Patientsconfirmed unresectable locally advanced or metastatic NSCLC patients;.
  4. Ability to provide qualified tumor samples..
  5. Patients must harbor the 1 of the 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., 19Del and L858R) as well as MET overexpression and/or amplification. MET overexpression and amplification must be confirmed by the central laboratory.
  6. No prior systemic anticancer therapy (including chemotherapy, radiotherapy, biological therapy, immunotherapy, or any investigational drugs) for locally advanced or metastatic NSCLC, and the participant is not amenable to curative surgery or radiotherapy. For patients with recurrent disease following prior surgery, if prior adjuvant chemo/radiotherapy, neoadjuvant chemo/radiotherapy, or definitive chemoradiotherapy for advanced disease was received, disease progression should have occurred ≥ 6 months after the completion of the last treatment.
  7. Presence of at least one measurable lesion at baseline according to RECIST v1.1. The target lesion must not have received prior irradiation, or if previously irradiated, must show documented evidence of disease progression after radiotherapy. Brain metastases cannot be selected as target lesions.
  8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
  9. Life expectancy ≥ 3 months.
  10. Adequate bone marrow reserve or organ function..
  11. Women of childbearing potential must use highly effective contraception. Women of childbearing potential must have a negative blood pregnancy test within 7 days before the first dose. Any male or female participant of childbearing potential must agree to use highly effective contraception throughout the study period and for 6 months after the last dose.

Exclusion Criteria:

  1. Prior treatment with any EGFR inhibitor or MET inhibitor.
  2. Concomitant driver alterations such as ALK, ROS1, RAS, BRAF, RET, and HER2 for which approved targeted therapies are clinically available, if the Investigator judges that the patients cannot benefit from this trial due to the concomitant alteration; or other alterations (e.g., those with substantial clinical evidence supporting a better intervention for the mutation) that, in the Investigator's judgment, preclude benefit from this trial..
  3. Prior antineoplastic therapy within 2 weeks prior to the first dose of study drug, including hormonal therapy, biologic therapy, immunotherapy (including but not limited to anti-PD-1/PD-L1 antibodies, anti-CTLA-4 antibodies, cellular immunotherapy, etc.), local infusion of antineoplastic agents, or Chinese herbal medicines and/or proprietary Chinese patent medicines with approved/intended indications for the treatment of lung cancer.
  4. Prior local radiotherapy (including radionuclide therapy such as strontium-89) within 2 weeks before the first dose of study drug; or, within 4 weeks before randomization, received bone marrow irradiation exceeding 30% or extensive-field radiotherapy..
  5. Clinically uncontrolled (requiring paracentesis or drainage) malignant pleural effusion, ascites, or pericardial effusion within 2 weeks prior to the first dose of study drug.
  6. Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study drug, or anticipated need for major surgery during the study period. Minor clinical procedures such as vascular access placement and core/needle biopsies are permitted.
  7. Presence of leptomeningeal carcinomatosis; presence of spinal cord compression; or symptomatic and unstable brain metastases, unless the participant has completed definitive treatment, has achieved neurological stability for at least 2 weeks prior to randomization, and requires no corticosteroids or anticonvulsants. Asymptomatic patients with brain metastases (e.g., without neurological deficits, seizures, or other typical signs/symptoms of central nervous system [CNS] metastasis) may be enrolled if the investigator assesses that there is no indication for immediate definitive intervention.
  8. Use of strong CYP3A4 inducers within 2 weeks prior to the first dose of study drug, or inability to discontinue strong CYP3A4 inducers during the study period.
  9. History of autoimmune diseases, immunodeficiency disorders (including positive HIV serology), other acquired or congenital immunodeficiency diseases, or history of solid organ or bone marrow transplantation.
  10. Active infection (e.g., the participant is receiving anti-infective therapy).
  11. Severe or uncontrolled cardiovascular diseases requiring medical treatment.
  12. History of hypersensitivity to the active or inactive excipients of osimertinib, gumarontinib/placebo, or chemotherapy agents (pemetrexed and cisplatin/carboplatin), or to drugs of similar chemical structure or class; contraindications to chemotherapy agents (pemetrexed and cisplatin/carboplatin).
  13. Failure to adequately recover from toxicities and/or complications resulting from any prior interventions prior to treatment initiation (i.e., not recovered to Grade ≤ 1, excluding fatigue or alopecia).
  14. Current diagnosis of other malignancies or a history of other active malignancies within 5 years prior to the first study treatment, with the exception of clinically cured localized neoplasms (e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, or papillary thyroid carcinoma).
  15. Definite prior history of neurological or psychiatric disorders, including epilepsy or dementia.
  16. Pregnant or lactating women.
  17. Participation in another investigational drug clinical trial and receipt of investigational drug within 3 weeks prior to the first dose of study drug.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A

Glumetinib 300 mg orally once daily (QD) + Osimertinib 80 mg orally QD,every 3 weeks

Glumetinib 300 mg QD orally under fasting conditions

Administered orally at a dose of 80 mg QD orally

Placebo komparator: Arm B

Placebo 300 mg orally QD + Osimertinib 80 mg orallyQD,every 3 weeks

Administered orally at a dose of 80 mg QD orally

Placebo 300 mg QD orally under fasting conditions

Aktiv komparator: Arm C

Osimertinib 80 mg QD and platinum-based chemotherapy Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Administered orally at a dose of 80 mg QD orally

Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
FS as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled

Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

Up to approximately 42 months after the first patient is enrolled

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
ORR as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled

Objective response rate (ORR) as assessed by IRC

Up to approximately 42 months after the first patient is enrolled
DCR as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled

Disease control rate (DCR) as assessed by IRC

Up to approximately 42 months after the first patient is enrolled
DOR as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled

Duration of Response (DOR) as assessed by IRC

Up to approximately 42 months after the first patient is enrolled
TTR as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled

Time to Response (TTR) as assessed by IRC

Up to approximately 42 months after the first patient is enrolled
PFS as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled

PFS as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
ORR as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled

ORR as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
DCR as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled

DCR as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
DOR as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled

DOR as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
TTR as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled

TTR as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
OS
Tidsramme: Up to approximately 42 months after the first patient is enrolled

Overall Survival (OS)

Up to approximately 42 months after the first patient is enrolled
Safety
Tidsramme: Up to approximately 42 months after the first patient is enrolled

Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs), the other safety variables including physical examination, vital signs and laboratory examinations.

Up to approximately 42 months after the first patient is enrolled
PK parameters
Tidsramme: Up to approximately 42 months after the first patient is enrolled

Plasma concentration of Glumetinib

Up to approximately 42 months after the first patient is enrolled

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

31. desember 2026

Primær fullføring (Antatt)

30. april 2029

Studiet fullført (Antatt)

31. august 2030

Datoer for studieregistrering

Først innsendt

16. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .